Phase I study of doxorubicin (D) plus anti-insulin-like growth factor 1 receptor (IGF-1R) antibody cixutumumab (IMC-A12) in advanced soft tissue sarcoma (STS)

被引：0
|
作者：
Chugh, Rashmi
Griffith, Kent A.
Brockstein, Bruce
Undevia, Samir D.
Stadler, Walter Michael
Schuetze, Scott
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] NorthShore Univ HealthSyst, Chicago, IL USA
[3] Univ Chicago, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10028
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A PHASE I/II STUDY OF ERLOTINIB IN COMBINATION WITH THE ANTI-INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-1R) MONOCLONAL ANTIBODY IMC-A12 (CIXUTUMUMAB) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC).
    Weickhardt, Andrew J.
    Doebele, Robert C.
    Oton, Anna B.
    Dy, Grace
    Lettieri, Jannice
    Maxson, Delee A.
    Reynolds, Michelle
    Jackson, Mary K.
    Brown, Amy
    Adjei, Araba
    Fetterly, Gerald J.
    Adjei, Alex A.
    Camidge, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S606 - S606
  • [2] Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
    Chugh, R.
    Griffith, K. A.
    Davis, E. J.
    Thomas, D. G.
    Zavala, J. D.
    Metko, G.
    Brockstein, B.
    Undevia, S. D.
    Stadler, W. M.
    Schuetze, S. M.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1459 - 1464
  • [3] A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer
    Weickhardt, Andrew
    Doebele, Robert
    Oton, Ana
    Lettieri, Janice
    Maxson, DeLee
    Reynolds, Michele
    Brown, Amy
    Jackson, Mary K.
    Dy, Grace
    Adjei, Araba
    Fetterly, Gerald
    Lu, Xian
    Franklin, Wilbur
    Varella-Garcia, Marileila
    Hirsch, Fred R.
    Wynes, Murry W.
    Youssoufian, Hagop
    Adjei, Alex
    Camidge, D. Ross
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) : 419 - 426
  • [4] Anti-tumor efficacy of IMC-A12, a fully human anti-insulin like growth factor 1 receptor (IGF-1R) antibody, against malignant mesothelioma (MM)
    Kaira, Neetu
    Zhang, Jingli
    Yu, Yunkai
    Ho, Mitchell
    Cao, Liang
    Hassan, Raffit
    CANCER RESEARCH, 2011, 71
  • [5] Teprotumumab Anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody Treatment of thyroid eye disease
    Desideri, L. Ferro
    Vagge, A.
    del Noce, C.
    Nicolo, M.
    Traverso, C. E.
    DRUGS OF THE FUTURE, 2020, 45 (01) : 21 - 25
  • [6] Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model (vol 26, pg 1459, 2015)
    Chugh, R.
    Griffith, K. A.
    Davis, E. J.
    Thomas, D. G.
    Zavala, J. D.
    Metko, G.
    Brockstein, B.
    Undevia, S. D.
    Stadler, W. M.
    Schuetze, S. M.
    ANNALS OF ONCOLOGY, 2019, 30 (08) : 1405 - 1405
  • [7] A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer
    Lin, Edward H.
    Lenz, Heinz-Josef
    Saleh, Mansoor N.
    Mackenzie, Mary J.
    Knost, James A.
    Pathiraja, Kumudu
    Langdon, Ronald B.
    Yao, Siu-Long
    Lu, Brian D.
    CANCER MEDICINE, 2014, 3 (04): : 988 - 997
  • [8] Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study.
    Rathkopf, D. E.
    Danila, D. C.
    Morris, M. J.
    Slovin, S. F.
    Borwick, L. S.
    Momen, L.
    Curley, T.
    Arauz, G.
    Larson, S. M.
    Fleisher, M.
    Rosen, N.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] A phase I study of the anti-insulin like growth factor type 1 receptor (IGF-1R) antibody dalotuzumab in pediatric patients with advanced solid tumors
    Frappaz, Didier
    McGregor, Lisa M.
    Pearson, Andrew Dj
    Gore, Lia
    DuBois, Steven G.
    Aerts, Isabelle
    Iannone, Robert
    Geschwindt, Ryan
    Van Schanke, Arne
    Wang, Ruixue
    Geoerger, Birgit
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] A phase I trial of the IGF-1R antibody IMC-A12 in combination with temsirolimus in patients with metastatic breast cancer
    Fleming, Gini F.
    Suman, VeraJean
    Goetz, Matthew P.
    Haluska, Paul
    Moynihan, Timothy Jerome
    Nanda, Rita
    Olopade, Olufunmilayo I.
    Pluard, Timothy J.
    Erlichman, Charles
    Chen, Helen X.
    Guo, Zhanfang
    Ellis, Matthew James
    Ma, Cynthia X.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345